An overview of international regulatory frameworks for mesenchymal stromal cell‐based medicinal products: From laboratory to patient
- 4 February 2020
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 40 (4) , 1315-1334
Abstract
Human mesenchymal stromal cells (hMSCs) are emerging as one of the most important cell types in advanced therapies and regenerative medicine due to their great therapeutic potential. The development of hMSC‐based products focuses on the use of hMSCs as biological active substances, and they are considered medicinal products by the primary health agencies worldwide. Due to their regulatory status, the development of hMSC‐based products is regulated by specific criteria that range from the design phase, nonclinical studies, clinical studies, to the final registration and approval. Patients should only be administered hMSC‐based products within the framework of a clinical trial or after the product has obtained marketing authorization; in both cases, authorization by health authorities is usually required. Considering the above, this paper describes the current general regulatory requirements for hMSC‐based products, by jurisdiction, to be implemented throughout their entire development process. These measures may provide support for researchers from both public and private entities and academia to optimize the development of these products and their subsequent marketing, thereby improving access to them by patients.Keywords
Funding Information
- Spanish Ministry of Science, Innovation and Universities (MICIU), State Plan for Scientific and Technical Research and Innovation (RTI2018-095410-BI00)
- Spanish Ministry of Economy, Industry and Competitiveness (FEDER funds, RD16/0011/0030, RTC-2016-5451-1)
This publication has 61 references indexed in Scilit:
- Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injuryJournal of Neuroinflammation, 2013
- Mesenchymal stem cells: a new trend for cell therapyActa Pharmacologica Sinica, 2013
- Large animal models for stem cell therapyStem Cell Research & Therapy, 2013
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical TrialsPLOS ONE, 2012
- Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical researchClinical and Experimental Medicine, 2012
- Safety of Mesenchymal Stem Cells for Clinical ApplicationStem Cells International, 2012
- The immune boundaries for stem cell based therapies: problems and prospective solutionsJournal of Cellular and Molecular Medicine, 2009
- Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass EffectStem Cells and Development, 2009
- Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative settingBlood, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006